181 related articles for article (PubMed ID: 37081322)
1. Relationship between Proclarix and the Aggressiveness of Prostate Cancer.
Campistol M; Triquell M; Regis L; Celma A; de Torres I; Semidey ME; Mast R; Mendez O; Planas J; Trilla E; Morote J
Mol Diagn Ther; 2023 Jul; 27(4):487-498. PubMed ID: 37081322
[TBL] [Abstract][Full Text] [Related]
2. PROPOSe: A Real-life Prospective Study of Proclarix, a Novel Blood-based Test to Support Challenging Biopsy Decision-making in Prostate Cancer.
Steuber T; Heidegger I; Kafka M; Roeder MA; Chun F; Preisser F; Palisaar RJ; Hanske J; Budaeus L; Schiess R; Keller T; Semjonow A; Hammerer P; Manka L; Ecke T; Schwentner C; Ohlmann C
Eur Urol Oncol; 2022 Jun; 5(3):321-327. PubMed ID: 33422560
[TBL] [Abstract][Full Text] [Related]
3. Proclarix, A New Biomarker for the Diagnosis of Clinically Significant Prostate Cancer: A Systematic Review.
Campistol M; Morote J; Regis L; Celma A; Planas J; Trilla E
Mol Diagn Ther; 2022 May; 26(3):273-281. PubMed ID: 35471698
[TBL] [Abstract][Full Text] [Related]
4. New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index.
Terracciano D; La Civita E; Athanasiou A; Liotti A; Fiorenza M; Cennamo M; Crocetto F; Tennstedt P; Schiess R; Haese A; Ferro M; Steuber T
Prostate; 2022 Nov; 82(15):1469-1476. PubMed ID: 35971798
[TBL] [Abstract][Full Text] [Related]
5. The Efficacy of Proclarix to Select Appropriate Candidates for Magnetic Resonance Imaging and Derived Prostate Biopsies in Men with Suspected Prostate Cancer.
Morote J; Campistol M; Celma A; Regis L; de Torres I; Semidey ME; Roche S; Mast R; Santamaría A; Planas J; Trilla E
World J Mens Health; 2022 Apr; 40(2):270-279. PubMed ID: 35021312
[TBL] [Abstract][Full Text] [Related]
6. Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?
Morote J; Campistol M; Regis L; Celma A; de Torres I; Semidey ME; Roche S; Mast R; Santamaria A; Planas J; Trilla E
Int J Biol Markers; 2022 Jun; 37(2):218-223. PubMed ID: 35200058
[TBL] [Abstract][Full Text] [Related]
7. Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging.
Morote J; Pye H; Campistol M; Celma A; Regis L; Semidey M; de Torres I; Mast R; Planas J; Santamaria A; Trilla E; Athanasiou A; Singh S; Heavey S; Stopka-Farooqui U; Freeman A; Haider A; Schiess R; Whitaker HC; Punwani S; Ahmed HU; Emberton M
BJU Int; 2023 Aug; 132(2):188-195. PubMed ID: 36855895
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Proclarix in the diagnostic work-up of prostate cancer.
Kaufmann B; Fischer S; Athanasiou A; Lautenbach N; Wittig A; Bieri U; Schmid FA; von Stauffenberg F; Scherer T; Eberli D; Gorin MA; Schiess R; Poyet C
BJUI Compass; 2024 Mar; 5(2):297-303. PubMed ID: 38371198
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI.
Campistol M; Morote J; Triquell M; Regis L; Celma A; de Torres I; Semidey ME; Mast R; Santamaría A; Planas J; Trilla E
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681685
[TBL] [Abstract][Full Text] [Related]
12. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
13. Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category.
Morote J; Campistol M; Triquell M; Celma A; Regis L; de Torres I; Semidey ME; Mast R; Santamaria A; Planas J; Trilla E
Eur Urol Open Sci; 2022 Mar; 37():38-44. PubMed ID: 35243388
[TBL] [Abstract][Full Text] [Related]
14. Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume.
Omri N; Kamil M; Alexander K; Alexander K; Edmond S; Ariel Z; David K; Gilad AE; Azik H
Prostate; 2020 Dec; 80(16):1444-1449. PubMed ID: 32970856
[TBL] [Abstract][Full Text] [Related]
15. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and oncological outcomes in negative multiparametric MRI patients undergoing robot-assisted radical prostatectomy.
Wagaskar VG; Ratnani P; Levy M; Moody K; Garcia M; Pedraza AM; Parekh S; Pandav K; Shukla B; Sobotka S; Haines K; Wiklund P; Tewari A
Prostate; 2021 Aug; 81(11):772-777. PubMed ID: 34057211
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Feb; 20(1):176-81. PubMed ID: 24771079
[TBL] [Abstract][Full Text] [Related]
18. Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging.
Meijer D; van Leeuwen PJ; Donswijk ML; Boellaard TN; Schoots IG; van der Poel HG; Hendrikse HN; Oprea-Lager DE; Vis AN
BJU Int; 2022 Jan; 129(1):54-62. PubMed ID: 34028165
[TBL] [Abstract][Full Text] [Related]
19. Radical Prostatectomy Findings in White Hispanic/Latino Men With NCCN Very Low-risk Prostate Cancer Detected by Template Biopsy.
Kryvenko ON; Lyapichev K; Chinea FM; Prakash NS; Pollack A; Gonzalgo ML; Punnen S; Jorda M
Am J Surg Pathol; 2016 Aug; 40(8):1125-32. PubMed ID: 27158756
[TBL] [Abstract][Full Text] [Related]
20. The risks of prostate cancer detection by transrectal ultrasound guide biopsy in Thai men with abnormal prostatic-specific antigen or abnormal digital rectal examination.
Leewansangtong S; Tantiwong A; Ratanarapee S; Nualyong C; Soontrapa S
J Med Assoc Thai; 2000 Dec; 83(12):1519-24. PubMed ID: 11253893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
